Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Opko's long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change
Pfizer

Pfizer and partner Opko ended 2016 on a disappointing note after their long-acting drug for growth hormone deficiency failed a phase III trial.

hGH-CTP has been held up as a possible blockbuster drug that would provide a once-weekly alternative to current human growth hormone (hGH) products that need to be dosed daily, including Pfizer's own Genotropin which made $425m in the first nine months of 2016. Overall, the market for hGH products is more than $3bn a year.

The phase III trial revealed that hGH-CTP failed to achieve the primary endpoint of significant change in the amount of torso fat versus placebo, sparking a sell-off in Opko share's around the turn of the year. The primary endpoint was the change in torso fat mass from baseline to week 26 of treatment.

Opko put a brave face on the finding, saying it could have been skewed by "one or more outliers" that affected the primary outcome. The company said it intends to review the data and it may still be able to include the results in future marketing applications, without having to do a second study.

"A greater percentage of subjects on hGH-CTP normalised serum concentrations of insulin-like growth factor-1 (IGF-1) compared to placebo," it said. IGF-1 activity is used as a surrogate marker to measure how well hGH therapy is working.

Meanwhile, Opko is pressing ahead with a pivotal phase III study in pre-pubertal growth hormone deficient children, which got underway as 2016 drew to a close.

Pfizer licensed rights to hGH-CTP in 2014 in a deal valued at more than $570m, with $275m of that coming from regulatory milestones, according to Opko's executive vice president Steven Rubin.

Opko is vying to be first to market with other long-acting hGH developers, including hGH market heavyweight Novo Nordisk which has somapacitan (NNC0195-0092) in phase III testing. Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.

Article by
Phil Taylor

3rd January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Getting the most out of your agency - a guide to developing a dynamic and rewarding relationship with your agency partner
...
Empowering nurses to transform patient care
As Sustainability and Transformation Plans (STPs) turn to action across England, Page & Page’s Communications Director Cori Hollenbach explores whether healthcare companies are considering the influence nurses can have on...
digital health stock resized
Making digital health personal
What makes a tool successfully support adherence and deliver value-based care?...

Infographics